APA (7th ed.) Citation

Bob-Ume, N. C., Omotoso, E. O., Bob-Ume, C. S., Akpabio, J. S., Akpabio, S. S., Bob-Ume, K. C., . . . Oladipupo, A. A. (2026). Kygevvi (doxecitine and doxribtimine) for thymidine kinase 2 deficiency: A turning point for an ultra-rare mitochondrial disorder. Journal of Rare Diseases, 5(1), 1. https://doi.org/10.1007/s44162-026-00209-y

Chicago Style (17th ed.) Citation

Bob-Ume, Nwamaka Chidera, et al. "Kygevvi (doxecitine and Doxribtimine) for Thymidine Kinase 2 Deficiency: A Turning Point for an Ultra-rare Mitochondrial Disorder." Journal of Rare Diseases 5, no. 1 (2026): 1. https://doi.org/10.1007/s44162-026-00209-y.

MLA (9th ed.) Citation

Bob-Ume, Nwamaka Chidera, et al. "Kygevvi (doxecitine and Doxribtimine) for Thymidine Kinase 2 Deficiency: A Turning Point for an Ultra-rare Mitochondrial Disorder." Journal of Rare Diseases, vol. 5, no. 1, 2026, p. 1, https://doi.org/10.1007/s44162-026-00209-y.